ATOS - Atossa Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.5900
-0.0800 (-3.00%)
As of 10:05AM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.6700
Open2.6800
Bid2.6000 x 800
Ask2.6300 x 3200
Day's Range2.5500 - 2.7300
52 Week Range0.7600 - 3.2500
Volume102,140
Avg. Volume815,375
Market Cap23.85M
Beta (5Y Monthly)2.84
PE Ratio (TTM)N/A
EPS (TTM)-2.1870
Earnings DateAug 11, 2020 - Aug 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
  • GlobeNewswire

    SARS-CoV-2 was spreading in the United States in late December 2019 and may have killed over 440 patients in California and 980 nationwide by mid-January 2020

    Dr. Steven Quay, MD, PhD, physician-scientist and CEO of Atossa Therapeutics, Inc. announced today that he and Dr. Martin Lee, PhD, Adjunct Professor of Statistics, UCLA Fielding School of Public Health, UCLA, Los Angeles, CA have published a manuscript entitled, “SARS-CoV-2 was spreading in the United States in late December 2019 and may have killed over 440 patients in California and 980 nationwide by mid-January.” The manuscript is available here: SARS in the US in Dec 2019.

  • GlobeNewswire

    Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical Study

    Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that it has begun the development of a second COVID-19 program using its proprietary drug candidate AT-301, to be administered by nasal spray. AT-301 is Atossa’s proprietary formula intended for nasal administration in patients immediately following diagnosis of COVID-19 but who have not yet exhibited symptoms severe enough to require hospitalization. Atossa also intends to conduct testing to determine whether AT-301 can be used as a prophylaxis to prevent or mitigate SARS-CoV-2, with the goal that it could become a “bridge to the vaccine” and be useful in the next phase of the coronavirus pandemic.

  • GlobeNewswire

    Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

    Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced the successful results from in vitro testing of AT-H201, Atossa’s proprietary COVID-19 drug candidate. The preliminary study results show that AT-H201 inhibits SARS-CoV-2 infectivity of VERO cells in a laboratory culture, which are the standard cell types being used to study infectivity of the coronavirus. AT-H201 components inhibited SARS-CoV-2 from infecting VERO cells in a laboratory culture.

  • GlobeNewswire

    Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs

    SEATTLE, May 13, 2020 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of.

  • GlobeNewswire

    Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment

    Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced positive interim results from its Phase 2 study of oral Endoxifen to treat breast cancer in the window of opportunity between diagnosis of breast cancer and surgery. A statistically significant (p = 0.031) reduction of about 74% in tumor cell proliferation was achieved over the 22 days of dosing. Proliferation was measured by Ki-67, a recognized standard measurement of breast cancer cell proliferation.

  • GlobeNewswire

    Atossa Therapeutics Receives FDA Feedback on Two Ongoing Programs

    Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced it has received feedback from the U.S. Food and Drug Administration (FDA) regarding two ongoing programs. The FDA recently provided written input on Atossa’s clinical path for oral Endoxifen to reduce mammographic breast density, or MBD. The input received from the FDA was very useful and will inform Atossa’s clinical trial strategy and study design both in the U.S. and in Stockholm, Sweden where Atossa is planning a Phase 2 study to reduce MBD.

  • GlobeNewswire

    Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study

    Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need, today announced that it has contracted with NYC Health + Hospitals/Metropolitan in New York City to conduct the NY HOPE Study of Atossa’s proprietary combination drug therapy called AT-H201. The NY HOPE Study will evaluate AT-H201 in COVID-19 patients on ventilators with the goal of reducing the amount of time on ventilators. “We are honored to be working with NYC Health + Hospitals/Metropolitan and Dr. Getaw Hassen, who are on the front lines of this unprecedented health crisis,” stated Dr. Steven Quay, President and CEO of Atossa Therapeutics.

  • Atossa Genetics Joins the Race to Find COVID-19 Treatment; Analyst Says ‘Buy’
    SmarterAnalyst

    Atossa Genetics Joins the Race to Find COVID-19 Treatment; Analyst Says ‘Buy’

    The world’s focus has zeroed in on healthcare companies. Hardly a surprising turn of events in these pandemic driven times. The search for a treatment or vaccine for COVID-19 has thrust into the limelight a host of smaller operators, who otherwise would have most likely remained under the wider public’s radar. The latest to join the race for a viable treatment is nano-cap Atossa Genetics (ATOS).Last week, shares of Atossa shot up by 35% following a launch announcement of a drug development program for COVID-19, called COVID-19 HOPE (AT-H201).The program consists of a combination of two undisclosed drugs already approved by the FDA for other diseases. The goal is to develop a therapy which will reduce the amount of time COVID-19 patients are on ventilators by improving lung function. Due to the large number of COVID-19 patients needing mechanical ventilation, hospitals are facing ventilator shortages, an issue Atossa hopes to solve with its novel offering.The company has filed provisional patent applications for the treatment and plans to apply to the FDA for approval to begin a clinical study under the Coronavirus Treatment Acceleration Program.Performing similarly to how antibodies against the virus would after a patient is vaccinated or immune, the purpose of AT-H201 is to block the ability of the virus to enter the target cells by mimicking the function of the antibodies formed from a vaccine.Maxim’s Jason McCarthy applauds Atossa’s “differentiated approach.” The analyst reiterated a Buy on ATOS along with a $4 price target, which implies an impressive 90% should the analyst’s target be met over the next 12 months. (To watch McCarthy’s track record, click here)McCarthy said, “The COVID pandemic needs testing, therapeutics and a vaccine. In reality, an effective vaccine is likely 12-18+ months away, and that would still be incredibly fast, in our view… As such having adequate testing and therapeutics which can 'blunt' the pandemic is critical, and all options are on the table.” (See Atossa stock analysis on TipRanks) More recent articles from Smarter Analyst: * Microsoft Reveals 4 New Surface Products Including Release Date For $199 Earbuds * All Eyes on Uber, Lyft Ahead of Earnings; Top Analyst Says 'Buy' * U.S. Air Carriers Lose More Than $10 Billion a Month - Report * 2 "Strong Buy" Dividend Stocks Yielding at Least 10%

  • GlobeNewswire

    Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study

    Atossa Therapeutics, Inc. (ATOS), has applied to the FDA for approval to commence a clinical study of its proprietary drug, AT-H201, in COVID-19 patients on mechanical ventilation. AT-H201 is a novel formulation of two pharmaceuticals previously approved by the FDA for other diseases. The goal of the clinical trial, called the HOPE Study, is to demonstrate improved lung function and reduce the amount of time that COVID-19 patients are on ventilators.

  • GlobeNewswire

    COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted

    Physician-scientist and inventor Dr. Steven Quay, MD, PhD announced today that his proprietary model of COVID-19 case growth predicts that the United States as a whole will be able to declare a SARS-CoV-2 “cease fire” on April 23, 2020, although individual states will continue to battle the pandemic. Many of the Administration’s initiatives have been successfully used by Taiwan to contain the virus and then permit the country to return to near normal.

  • GlobeNewswire

    Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program

    Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need, today announced a new drug development program called COVID-19 HOPE. The program uses a novel combination of two drugs that have been previously approved by the FDA for other diseases. The goal of the COVID-19 HOPE program is to develop a therapy to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators.

  • GlobeNewswire

    Atossa Therapeutics Announces Clinical Progress

    Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced recent progress with its Phase 2 study administering oral Endoxifen in the “window of opportunity” between diagnosis of breast cancer and surgery, as well as the company’s proposed Phase 2 clinical trial to reduce mammographic breast density (MBD). Completed treating a sufficient number of patients to permit an initial report of study results from the pilot portion of the study.

  • GlobeNewswire

    New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients

    Physician-scientist and inventor Dr. Steven Quay, MD, PhD, is announcing a new combination treatment with the potential to improve pulmonary function and reduce or eliminate mechanical ventilation in patients with the coronavirus infection. The treatment uses two drugs previously approved by the FDA for other conditions: nebulized (inhaled as a fine mist) heparin combined with N-acetylcysteine (NAC), termed “H-NAC."

  • GlobeNewswire

    Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update

    SEATTLE, March 26, 2020 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat.

  • GlobeNewswire

    Atossa Therapeutics Announces Upcoming Meeting with FDA

    Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today that it will meet with the U.S. FDA on April 30, 2020. The objective of this meeting is to discuss the clinical development of oral Endoxifen to reduce mammographic breast density (MBD). "This important meeting with the FDA is a critical step in developing our oral Endoxifen for the U.S. market,” commented Janet R. Rea, SVP Regulatory, Quality and Clinical Affairs.

  • GlobeNewswire

    Atossa Therapeutics, Inc. Files for Swedish Regulatory Approval to Initiate a Phase 2 Study of Oral Endoxifen to Reduce Mammographic Breast Density

    Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it has filed with the Swedish Medical Product Agency and the Institutional Review Board to initiate a Phase 2 study of its oral Endoxifen for the reduction of mammographic breast density (MBD). MBD is an emerging public health issue affecting more than 10 million women in the United States. Studies conducted by others have shown that MBD increases the risk of developing breast cancer, and reducing MBD can reduce the incidence of breast cancer.

  • GlobeNewswire

    Atossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

    SEATTLE, Feb. 05, 2020 -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast.

  • ACCESSWIRE

    Interview with Atossa Therapeutics' Kyle Guse On World Cancer Day "Transforming Breast Cancer Treatment"

    Every February 4th is World Cancer Day , the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awareness, improving education and catalyzing personal, ...

  • GlobeNewswire

    Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020

    During 2019, we focused on developing our proprietary drug Endoxifen to reduce mammographic breast density (MBD) and to treat breast cancer after a woman is diagnosed but before her surgery. MBD is an emerging public health issue affecting over 10 million women in the United States.

  • GlobeNewswire

    Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.

    Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that its corporate name change from "Atossa Genetics Inc." to "Atossa Therapeutics, Inc." became effective at 12:01 a.m. ET today, January 6, 2020. "Over the last several years, we have transitioned the Company’s focus on developing therapies to treat breast cancer, breast density and other breast conditions," said Steve Quay, Ph.D., M.D., president and CEO of Atossa.

  • GlobeNewswire

    Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women

    Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it has contracted with Stockholm South General Hospital in Sweden to conduct a Phase 2 study of Atossa’s proprietary oral Endoxifen to reduce mammographic breast density (MBD) in women. MBD is an emerging public health issue, as studies conducted by others have shown that MBD increases the risk of developing breast cancer and that reducing MBD can reduce the incidence of breast cancer.

  • Is Atossa Genetics (NASDAQ:ATOS) In A Good Position To Deliver On Growth Plans?
    Simply Wall St.

    Is Atossa Genetics (NASDAQ:ATOS) In A Good Position To Deliver On Growth Plans?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019

    SEATTLE, Dec. 05, 2019 -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer.

  • GlobeNewswire

    Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update

    SEATTLE, Nov. 13, 2019 -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast.

  • GlobeNewswire

    Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference

    SEATTLE, Oct. 23, 2019 -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer.